Clinical Trials - February 18, 2021
Nordic Nanovector provides Phase II trial update
Nordic Nanovector provides an update on PARADIGME, its ongoing Phase 2b trial of Betalutin in 3rd-line relapsed/refractory follicular lymphoma. Despite COVID has the company seen a significant improvement in the enrolment rate from approximately two to approximately five patients per month, it states. After the expected lessening of COVID restrictions plus the ongoing operational improvements, […]
Clinical Trials - December 6, 2020
Nordic Nanovector completes patient enrolment into Phase 1 trial
Nordic Nanovector has completed enrolment into the LYMRIT 37-05 Phase 1 clinical trial of Betalutin (177Lu lilotomab satetraxetan) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) not eligible for autologous stem cell transplantation (ASCT). Eighteen DLBCL patients were enrolled into the trial at clinical trial sites in the US and Europe and were […]
Clinical Trials - November 28, 2020
Nordic Nanovector completes enrolment in Phase 1b trial
Nordic Nanovector has enrolled the final two patients into the second safety cohort of its Phase 1 Archer-1 (LYMRIT 37-07) trial investigating safety and preliminary efficacy of Betalutin (177Lu lilotomab satetraxetan) in combination with rituximab in 2nd-line follicular lymphoma (2L FL). The dosing regimen in this cohort is a single administration of 15 MBq/kg Betalutin […]
Intellectual Property - August 14, 2020
Nordic Nanovector announces EU patent granted
Nordic Nanovector has announced the grant of an EU patent covering the use of Alpha37 for the treatment of Chronic Lymphocytic Leukemia (CLL) and non-Hodgkin’s lymphoma (NHL). Alpha37 is an investigational radioimmunoconjugate developed by Nordic Nanovector in collaboration with Orano Med comprising a proprietary chimeric CD37-targeting antibody conjugated to the alpha-particle generating radionuclide lead-212. Alpha37 […]
In a new job - August 13, 2020
Nordic Nanovector appoints new CMO
Nordic Nanovector announces that Christine Wilkinson Blanc has been appointed Chief Medical Officer with immediate effect. Wilkinson Blanc is a seasoned pharmaceutical physician with broad experience in oncology and haematology with both large pharmaceutical and emerging biotechnology companies. She has over 25 years of experience in the pharmaceutical industry and has led multiple clinical studies […]
Clinical Trials - July 2, 2020
Nordic Nanovector to amend trial protocol
Nordic Nanovector will amend the trial protocol for its PARADIGME trial to broaden the inclusion criteria and expand the pool of eligible patients with the aim of increasing the present rate of enrolment. This decision has been made based on the company’s reviewed discussions with the US Food and Drug Administration (FDA). PARADIGME PARADIGME is […]
